Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 7/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 5/20 | 0.53 |
| ▸ | LIPE | Q05469 | 1/20 | 0.45 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.42 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.42 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL940743 | 0.94 | PTGS2 (0.57) | PTGS2PTGS1LIPECYP11B1CYP11B2 | |
| SCHEMBL10833553 | 0.85 | PTGS2 (0.51) | PTGS2PTGS1LIPECYP11B1CYP11B2 | |
| SCHEMBL20325535 | 0.82 | LIPE (0.48) | PTGS2PTGS1LIPENFE2L2MEN1 | |
| SCHEMBL7994583 | 0.78 | PTGS2 (0.56) | PTGS2PTGS1GPR119SMN1; SMN2MEN1 | |
| SCHEMBL29504605 | 0.77 | KDM4E (0.59) | PTGS2PTGS1MEN1KMT2A | |
| SCHEMBL1477426 | 0.77 | PTGS2 (0.57) | PTGS2PTGS1 | |
| SCHEMBL19435036 | 0.77 | KDM4E (0.59) | PTGS2PTGS1MEN1KMT2A | |
| SCHEMBL7363201 | 0.75 | PTGS2 (0.56) | PTGS2PTGS1CYP11B1CYP11B2SMN1; SMN2 | |
| SCHEMBL10833967 | 0.74 | DAGLA (0.44) | PTGS2PTGS1LIPEP2RX3DAGLA | |
| SCHEMBL12386850 | 0.74 | KDM4E (0.58) | LIPEP2RX3SMN1; SMN2MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040127528-A1 | Metalloproteinase inhibitors | ASTRAZENECA AB (SE) | 2004-07-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127528-A1 | Metalloproteinase inhibitors | MMP9, MMP10, MMP3 | PTGS2 128/4885PTGS1 137/4885LIPE 1752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.